FDC Nivolumab + Relatlimab + rHuPH20 Injection

DRUG3 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company

Conditions

Advanced Solid TumorsMelanomaPreviously Untreated Metastatic or Unresectable Melanoma

Phase 1

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors

RecruitingCTIS2024-516602-28-00

Bristol-Myers Squibb Services Unlimited CompanyAdvanced Solid Tumors

Start: 2025-11-21Target: 62Updated: 2026-01-19

Phase 2

A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma

Active, not recruitingCTIS2023-504515-33-00

Bristol-Myers Squibb Services Unlimited CompanyMelanoma

Start: 2024-02-19Target: 82Updated: 2026-01-05

Phase 3

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma

RecruitingCTIS2022-500967-11-00

Bristol-Myers Squibb Services Unlimited CompanyPreviously Untreated Metastatic or Unresectable Melanoma

Start: 2023-07-06Target: 423Updated: 2026-01-13